Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

P682: NEMTABRUTINIB (MK-1026), A NON-COVALENT INHIBITOR OF WILD-TYPE AND C481S MUTATED BRUTON TYROSINE KINASE FOR B-CELL MALIGNANCIES: EFFICACY AND SAFETY OF THE PHASE 2 DOSE-EXPANSION BELLWAVE-001 STUDY
Woyach, Jennifer A. , Eradat, Herbert, Brander, Danielle M. , Tees, Michael, Wang, W., Reddy, Nishitha , Farooqui, Mohammed, Flinn, Ian W. , Awan, Farrukh T. , Parikh, Sameer A. , Phillips, Tycel , Byrd, John C. , Stephens, Deborah M.

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 578-579

10.1097/01.hs9.0000845612.25766.0c Get It

P656: INCIDENT VENOUS THROMBOEMBOLISM (VTE) IN PATIENTS WITH MONOCLONAL B-CELL LYMPHOCYTOSIS (MBL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) – A POPULATION-BASED STUDY
Koehler, A., Moise, M., Call, T., Rabe, K., Achenbach, S., Crusan, D. J., Bailey, K., Petterson, T., Ding, W., Kenderian, S., Leis, J., Wang, Y., Muchtar, E., Hampel, P., Schwager, S., Slager, S., Kay, N., Ashrani, A., Parikh, S., Rabe, K. G., Crusan, Daniel J. , Leis, Joe, Wang, Yucai , Hampel, Paul J. , Slager, Susan, Parikh, Sameer A.

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 554-555

10.1097/01.hs9.0000845508.29001.67 Get It

P651: VENETOCLAX-BASED TREATMENT OF PATIENTS WITH RICHTER SYNDROME: OUTCOMES FROM A MULTICENTER RETROSPECTIVE STUDY
Hampel, P., Parikh, S., Wierda, W., Ferrajoli, A., Jain, N., Burger, J., Call, T., Wang, Y. , Kenderian, S., Ding, W., Hampel, Paul J. , Parikh, Sameer A. , Wierda, William G. , Jain, N., Wang, Y., Kenderian, S., Thompson, Philip A

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 549-550

10.1097/01.hs9.0000845488.18043.aa Get It

Phenotype, Function, and Clinical Significance of CD26+ and CD161+Tregs in Splenic Marginal Zone Lymphoma
Tang, Xinyi , Anagnostou, Theodora , Wu, Xiaosheng , Krull, Jordan E. , Wenzl, Kerstin , Mondello, Patrizia , Bhardwaj, Vaishali , Wang, Junwen , Novak, Anne J. , Ansell, Stephen M. , Anagnostou, Theodora , Krull, Jordan E , Mondello, Patrizia , Bhardwaj, Vaishali , Ansell, Stephen M , Wang, Junwen , Yang, Zhi-Zhang , Kim, Hyo Jin , Yu, Yue , Chen, Jun

Mayo Clinic

Clinical Cancer Research | June 23, 2022 | Volume: 28 | Issue: 19 | Pages: 4322-4335

10.1158/1078-0432.ccr-22-0977 | PMID 35686915 Get It

Abstract Purpose: Regulatory T-cells (Treg) are essential to Tregs homeostasis and modulate the antitumor immune response in patients with lymphoma. However, the biology and prognostic impact of Tregs in splenic marginal zone lymphoma (SMZL) have not been studied. Experimental Design: Biopsy specimens from 24 patients with SMZL and 12 reactive spleens (rSP) from individuals without lymphoma were analyzed by using CITE-seq (cellular indexing of transcriptomes and epitopes by sequencing), CyTOF (mass cytometry) analysis, and flow cytometry to explore the phenotype, transcriptomic profile, and clinical significance of intratumoral Tregs and their subsets. The biological characteristics and cell signaling pathways of intratumoral Treg subsets were confirmed by in vitro functional assays. Results: We found that Tregs are more abundant in SMZL patients' spleens than rSP, and Tregs from patients with SMZL and rSP can be separated into CD161+Treg and CD26+Treg subsets. CD161+Tregs are increased in SMZL but have dysregulated immune function. We found that CD161+Treg and CD26+Tregs have unique gene expression and phenotypic profiles and are differentially correlated with patient outcomes. Specifically, increased CD161+Tregs are significantly associated with a favorable prognosis in patients with SMZL, whereas CD26+Tregs are associated with a poor prognosis. Furthermore, activation of the IL2/STAT5 pathway contributes to the induction of CD26+Tregs and can be reversed by STAT5 inhibition. Conclusions: IL2/STAT5-mediated expansion of CD26+Tregs contributes to a poor clinical outcome in SMZL and may represent a therapeutic opportunity in this disease.
S201: CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN AN OPEN-LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)
Ansell, S., Maddocks, Kami J. , Bence‐Bruckler, I., Kline, J., Mayer, Jiřı́ , Caimi, Paolo, Feldman, Tatyana , Hess, Brian , Eisen, S., Negievich, Yanina, Wang, L., Wuerthner, Jens, Herrera, Alex F. , Carlo‐Stella, Carmelo , Zinzani, Pier Luigi , Radford, John , Pinto, Antonio , Collins, Graham P. , Bachanová, Veronika , Bartlett, Nancy L. , Hamadani, Mehdi , Savage, Kerry J. , Advani, Ranjana H. , Casasnovas, Olivier , Bastos‐Oreiro, Mariana , Iyengar, Sunil

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 102-103

10.1097/01.hs9.0000843696.37630.1c Get It

Detection of Anal Intraepithelial Neoplasia and Anal Squamous Cell Carcinoma on Colonoscopy
Voss, Jordan K. , Kurdi, Ahmed T. , Neto, Manuel B. Braga , Chedid, Victor , Neto, Manuel Braga, Chedid, Victor G , Braga Neto, Manuel B , Wang, Xiao‐Jing

Mayo Clinic

ACG Case Reports Journal | June 22, 2022 | Volume: 9 | Issue: 6 | Pages: e00792

10.14309/crj.0000000000000792 | PMID 35756724 Get It

ABSTRACT The purpose of this case series is to review the endoscopic detection of anal intraepithelial neoplasia and anal squamous cell carcinoma including the role of rectal retroflexion and narrow-band imaging. Four cases of anal intraepithelial neoplasia were incidentally discovered in women aged 55–71 years. Anal lesions identified included sessile polyps, nodular mucosa, and circumferential polyps. A fifth patient, who presented with abdominal pain, was found to have a 3 cm anal squamous cell carcinoma on diagnostic colonoscopy, despite a negative colonoscopy 21 months earlier. In the absence of contraindications, retroflexion should be performed on all patients. Suspicious anal mucosa warrants biopsy.
Genome-wide methylation profiling reveals differentially methylated genes in blood DNA of small-cell lung cancer patients
He, Yanqi , Wei, Calvin R. , Cunningham, Julie M. , Yang, Ping , Wei, Calvin, Sun, Zhifu , Wang, Liang , Wei, Zong

Mayo Clinic

Precision Clinical Medicine | June 22, 2022 | Volume: 5 | Issue: 3 | Pages: No page available

10.1093/pcmedi/pbac017 | PMID 35875603 Get It

Mortality after multivessel revascularisation involving the proximal left anterior descending artery
Ono, Masafumi , Hara, Hironori , Gao, Chao , Kawashima, Hideyuki , Wang, Rutao , O’Leary, Neil , Mack, Michael J. , Holmes, David R. , Morice, Marie‐Claude, Head, Stuart J., Davierwala, Piroze , Mohr, Friedrich W., Garg, Scot , Onuma, Yoshinobu , Bochenek, Andrzej , Escaned, Javier , Curzen, Nick , Garg, Scot , Serruys, Patrick W , Curzen, Nick , Onuma, Yoshinobu , Escaned, Javier , Wykrzykowska, Joanna J. , Piek, Jan J , Kappetein, A. Pieter , Noack, Thilo , Serruys, Patrick W.

Mayo Clinic

Heart | June 22, 2022 | Volume: 108 | Issue: 22 | Pages: 1784-1791

10.1136/heartjnl-2022-320934 | PMID 35732441 Get It

Objective We sought to investigate whether long-term clinical outcomes differ following percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) in patients with three-vessel disease (3VD) and lesions in the proximal left anterior descending artery (P-LAD). Methods This post-hoc analysis of the Synergy between PCI with Taxus and Cardiac Surgery (SYNTAX) Extended Survival study included patients with 3VD who were classified according to the presence or absence of lesions located in the P-LAD. Ten-year all-cause death and 5-year major adverse cardiac or cerebrovascular events (MACCE) were assessed. Results Among 1088 patients with 3VD, 559 (51.4%) had involvement of P-LAD and their 10-year mortality was numerically higher following PCI versus CABG (28.9% vs 21.9%; HR: 1.39, 95% CI 0.99 to 1.95). Although patients without P-LAD lesions had significantly higher 10-year mortality following PCI compared with CABG, there was no evidence of a treatment-by-subgroup interaction (28.8% vs 20.2%; HR: 1.47, 95% CI 1.03 to 2.09, pinteraction=0.837). The incidence of MACCE at 5 years was significantly higher with PCI than CABG, irrespective of involvement of P-LAD (with P-LAD: HR: 1.86, 95% CI 1.36 to 2.55; without P-LAD: HR: 1.54, 95% CI 1.11 to 2.12; pinteraction=0.408). Individualised assessment using the SYNTAX Score II 2020 established that a quarter of patients with P-LAD lesions had significantly higher mortality with PCI than CABG, whereas in the remaining three-quarters CABG had similar mortality. Conclusions Among patients with 3VD, the presence or absence of a P-LAD lesion was not associated with any treatment effect on long-term outcomes following PCI or CABG. Trial registration number SYNTAXES: NCT03417050; SYNTAX: NCT00114972.
A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL)
Fischer, Luca , Patten, Piers , Smith, Sonali M. , Ubieto, Ana Jiménez , Davis, Keith L. , Nagar, Saurabh , Bollu, Vamsi , Jousseaume, Etienne, Ramos, Roberto , Link, Brian K. , Link, Brian K , Patten, Piers E M , Salles, Gilles , Schuster, Stephen J. , Kuruvilla, John , Tresckow, Bastian von , Zhang, Jie , Wang, Yucai

Mayo Clinic

HemaSphere | June 21, 2022 | Volume: 6 | Issue: 7 | Pages: e745

10.1097/hs9.0000000000000745 | PMID 35813099 Get It

This study (ReCORD-FL) sought to construct a historical control cohort to augment single-arm trials in relapsed/refractory follicular lymphoma (r/r FL). A retrospective study in 10 centers across North America and Europe was conducted. Adults with grade 1–3A FL were required to be r/r after ≥2 therapy lines including an anti-CD20 and an alkylator. After first becoming r/r, patients were required to initiate ≥1 additional therapy line, which defined the study index date. Endpoints were observed from start of each therapy line (including index line) until death, last follow-up, or December 31, 2020. Endpoints were complete response (CR) rate, overall response rate (ORR), time to next treatment or death (TNT-D), event-free survival (EFS), and overall survival (OS). One hundred eighty-seven patients were identified. Most patients’ (80.2%) index therapy occurred in third line (3L) (range, 3L–6L). Median follow-up from FL diagnosis was 9 years (range, 1–21 years). CR and ORR to the index therapy were 39.0% and 70.6%, respectively. Median (95% confidence interval) EFS from index was 14.6 (11.0-18.0) months; median OS from index was 10.6 years. Outcomes worsened across successive treatment lines and for patients who were double refractory (r/r to both an anti-CD20 monoclonal antibody and an alkylator) or POD24 (progressed ≤24 months after front-line anti-CD20) at index. Findings demonstrate the unmet need of FL patients with multiply relapsed, double refractory, or POD24 disease. Based on robustness of the historical data collected and comparability with a previous study (SCHOLAR-5), ReCORD-FL presents a valuable source of control data for comparative studies in r/r FL.
Distinct Reproductive Risk Profiles for Intrinsic-Like Breast Cancer Subtypes: Pooled Analysis of Population-Based Studies
Jung, Audrey , Ahearn, Thomas U. , Behrens, Sabine , Middha, Pooja , Bolla, Manjeet K. , Wang, Qin , Arndt, Volker , Aronson, Kristan J. , Brenner, Hermann , Eriksson, Mikael , Evans, D. Gareth , Hadjisavvas, Andreas , Haiman, Christopher A. , Håkansson, Niclas , Hamann, Ute , Hoppe, Reiner , Howell, Anthony , Hunter, David J. , Kosma, Veli‐Matti , Lissowska, Jolanta , Loizidou, Maria A. , Mannermaa, Arto , Maurer, Tabea, Olsson, Håkan , Patel, Alpa V , Perou, Charles M. , Shibli, Rana , Stone, Jennifer , Vachon, Celine M. , Wang, Sophia , Wu, Anna H. , Yang, Xiaohong R. , Zheng, Wei , Easton, Douglas F. , Chatterjee, Nilanjan , García‐Closas, Montserrat , Chang‐Claude, Jenny , Olsson, Håkan , Jung, Audrey Y , Becher, Heiko , Brenner, Hermann , Canzian, Federico , Czene, Kamila , Eliassen, A Heather , Figueroa, Jonine D , Fritschi, Lin , Gabrielson, Marike , Giles, Graham G , Guénel, Pascal , Hadjisavvas, Andreas , Håkansson, Niclas , Hall, Per N , Hüsing, Anika , Koutros, Stella , Kraft, Peter , Marchand, Loïc Le , Lissowska, Jolanta , Loizidou, Maria A , Mannermaa, Arto , Murphy, Rachel A , Olsson, Håkan , Patel, Alpa V , Perou, Charles M , Shu, Xiao-Ou , Southey, Melissa C , Stone, Jennifer , Tamimi, Rulla M , Vachon, Celine M. , Wolk, Alicja , Dunning, Alison M , Pharoah, Paul D P , Easton, Doug , Milne, Roger L , Schmidt, Marjanka K , García-Closas, Montserrat , Chang-Claude, Jenny , Behrens, Sabine , Evans, D Gareth , Arndt, Volker , Kapoor, Pooja Middha , Zheng, Wei , Eriksson, Mikael , Wang, Sophia S , Wang, Qin , Augustinsson, Annelie , Freeman, Laura E. Beane , Becher, Heiko , Canzian, Federico , Carey, Lisa A. , Czene, Kamila , Eliassen, A. Heather , Figueroa, Jonine D. , Fritschi, Lin , Gabrielson, Marike , Giles, Graham G. , Guénel, Pascal , Hopper, John L. , Hüsing, Anika , Kaaks, Rudolf , Koutros, Stella , Kraft, Peter , Lacey, James V. , Marchand, Loı̈c Le , Murphy, Rachel A. , Olshan, Andrew F. , Rennert, Gad , Shu, Xiao‐Ou , Southey, Melissa C. , Tamimi, Rulla M. , Teras, Lauren R. , Troester, Melissa A. , Truong, Thérèse , Wolk, Alicja , Dunning, Alison M. , Pharoah, Paul D.P. , Milne, Roger L. , Schmidt, Marjanka K.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | June 20, 2022 | Volume: 114 | Issue: 12 | Pages: 1706-1719

10.1093/jnci/djac117 | PMID 35723569 Get It

AbstractBackgroundReproductive factors have been shown to be differentially associated with risk of estrogen receptor (ER)-positive and ER-negative breast cancer. However, their associations with intrinsic-like subtypes are less clear.MethodsAnalyses included up to 23 353 cases and 71 072 controls pooled from 31 population-based case-control or cohort studies in the Breast Cancer Association Consortium across 16 countries on 4 continents. Polytomous logistic regression was used to estimate the association between reproductive factors and risk of breast cancer by intrinsic-like subtypes (luminal A-like, luminal B-like, luminal B-HER2–like, HER2-enriched–like, and triple-negative breast cancer) and by invasiveness. All statistical tests were 2-sided.ResultsCompared with nulliparous women, parous women had a lower risk of luminal A-like, luminal B-like, luminal B-HER2–like, and HER2-enriched–like disease. This association was apparent only after approximately 10 years since last birth and became stronger with increasing time (odds ratio [OR] = 0.59, 95% confidence interval [CI] = 0.49 to 0.71; and OR = 0.36, 95% CI = 0.28 to 0.46 for multiparous women with luminal A-like tumors 20 to less than 25 years after last birth and 45 to less than 50 years after last birth, respectively). In contrast, parous women had a higher risk of triple-negative breast cancer right after their last birth (for multiparous women: OR = 3.12, 95% CI = 2.02 to 4.83) that was attenuated with time but persisted for decades (OR = 1.03, 95% CI = 0.79 to 1.34, for multiparous women 25 to less than 30 years after last birth). Older age at first birth (Pheterogeneity < .001 for triple-negative compared with luminal A-like breast cancer) and breastfeeding (Pheterogeneity < .001 for triple-negative compared with luminal A-like breast cancer) were associated with lower risk of triple-negative breast cancer but not with other disease subtypes. Younger age at menarche was associated with higher risk of all subtypes; older age at menopause was associated with higher risk of luminal A-like but not triple-negative breast cancer. Associations for in situ tumors were similar to luminal A-like.ConclusionsThis large and comprehensive study demonstrates a distinct reproductive risk factor profile for triple-negative breast cancer compared with other subtypes, with implications for the understanding of disease etiology and risk prediction.